Good morning, team—Thursday, January 1, 2026 edition Here’s what really matters. Opening Recap...
Archive - January 1, 2026
BCAB: $40M SPV to Propel Oz-V into Key Trial!
Overview: BioAtla, Inc. (NASDAQ: BCAB) is a clinical-stage biotech specializing in Conditionally...